Somatostatin-Dopamine Chimeric Molecules in Neuroendocrine Neoplasms

Overview

Journal J Clin Med

Specialty General Medicine

Date 2021 Feb 4

PMID 33535394

Citations 9

Authors

Maria Celeste Cantone

Alessandra Dicitore

Giovanni Vitale

Affiliations

Soon will be listed here.

Abstract

Neuroendocrine neoplasms (NENs) are a widely heterogeneous family of neoplasms arising from neuroendocrine cells, which are interspersed throughout the body. Despite NENs are relatively rare, their incidence and prevalence are constantly increasing probably due to the improvement in earlier diagnosis and patients' management. When surgery is not curative, particularly for patients with metastatic disease, several medical options are available. Somatostatin analogues (SSA) are the first-line medical therapy for well-differentiated NENs. Interestingly, the heterodimerization of somatostatin receptors (s) with dopamine receptors (DRs) has been discovered in NENs. This phenomenon results in hybrid receptors with enhanced functional activity. On these bases, chimeric molecules embracing somatostatin and dopamine features have been recently developed. The aim of this review is to provide a comprehensive overview of the available preclinical and clinical data regarding chimeric somatostatin-dopamine agonists as a new class of "magic bullet" in the therapy of NENs.

Citing Articles

On-resin synthesis of Lanreotide epimers and studies of their structure-activity relationships.

Chowdhury A, Tripathi N, Jadav R, Gour V, Purohit P, Bandyopadhyay A RSC Med Chem. 2024; 15(8):2766-2772.

PMID: 39149098 PMC: 11324058. DOI: 10.1039/d4md00338a.

The State-of-the-Art Mechanisms and Antitumor Effects of Somatostatin in Colorectal Cancer: A Review.

Kasprzak A, Geltz A Biomedicines. 2024; 12(3).

PMID: 38540191 PMC: 10968376. DOI: 10.3390/biomedicines12030578.

Current and Emerging Pharmacological Therapies for Cushing's Disease.

Divaris E, Kostopoulos G, Efstathiadou Z Curr Pharm Des. 2024; 30(10):757-777.

PMID: 38424426 DOI: 10.2174/0113816128290025240216110928.

Computerized tomography-guided therapeutic percutaneous puncture catheter drainage-combined with somatostatin for severe acute pancreatitis: An analysis of efficacy and safety.

Zheng X, Li W, Lin Y, Huang T World J Gastrointest Surg. 2024; 16(1):59-66.

PMID: 38328327 PMC: 10845273. DOI: 10.4240/wjgs.v16.i1.59.

Dopamine agonist therapy for prolactinomas: do we need to rethink the place of surgery in prolactinoma management?.

De Sousa S Endocr Oncol. 2023; 2(1):R31-R50.

PMID: 37435462 PMC: 10259306. DOI: 10.1530/EO-21-0038.

References

Garcia E, Naves L, Silva A, de Castro L, Casulari L, Azevedo M . Short-term treatment with cabergoline can lead to tumor shrinkage in patients with nonfunctioning pituitary adenomas. Pituitary. 2012; 16(2):189-94. DOI: 10.1007/s11102-012-0403-y. View

Lemmer K, Ahnert-Hilger G, Hopfner M, Hoegerle S, Faiss S, Grabowski P . Expression of dopamine receptors and transporter in neuroendocrine gastrointestinal tumor cells. Life Sci. 2002; 71(6):667-78. DOI: 10.1016/s0024-3205(02)01703-4. View

Cives M, Kunz P, Morse B, Coppola D, Schell M, Campos T . Phase II clinical trial of pasireotide long-acting repeatable in patients with metastatic neuroendocrine tumors. Endocr Relat Cancer. 2014; 22(1):1-9. PMC: 4643672. DOI: 10.1530/ERC-14-0360. View

Hukovic N, Panetta R, Kumar U, Patel Y . Agonist-dependent regulation of cloned human somatostatin receptor types 1-5 (hSSTR1-5): subtype selective internalization or upregulation. Endocrinology. 1996; 137(9):4046-9. DOI: 10.1210/endo.137.9.8756582. View

Onofri C, Theodoropoulou M, Losa M, Uhl E, Lange M, Arzt E . Localization of vascular endothelial growth factor (VEGF) receptors in normal and adenomatous pituitaries: detection of a non-endothelial function of VEGF in pituitary tumours. J Endocrinol. 2006; 191(1):249-61. DOI: 10.1677/joe.1.06992. View

Pivonello R, Ferone D, Lombardi G, Colao A, Lamberts S, Hofland L . Novel insights in dopamine receptor physiology. Eur J Endocrinol. 2007; 156 Suppl 1:S13-S21. DOI: 10.1530/eje.1.02353. View

Maiter D . Management of Dopamine Agonist-Resistant Prolactinoma. Neuroendocrinology. 2018; 109(1):42-50. DOI: 10.1159/000495775. View

Ben-Shlomo A, Liu N, Melmed S . Somatostatin and dopamine receptor regulation of pituitary somatotroph adenomas. Pituitary. 2016; 20(1):93-99. DOI: 10.1007/s11102-016-0778-2. View

Gatto F, Barbieri F, Gatti M, Wurth R, Schulz S, Ravetti J . Balance between somatostatin and D2 receptor expression drives TSH-secreting adenoma response to somatostatin analogues and dopastatins. Clin Endocrinol (Oxf). 2011; 76(3):407-14. DOI: 10.1111/j.1365-2265.2011.04200.x. View

10.

Alexandraki K, Tsoli M, Kyriakopoulos G, Angelousi A, Nikolopoulos G, Kolomodi D . Current concepts in the diagnosis and management of neuroendocrine neoplasms of unknown primary origin. Minerva Endocrinol. 2019; 44(4):378-386. DOI: 10.23736/S0391-1977.19.03012-8. View

11.

Zitzmann K, Andersen S, Vlotides G, Spottl G, Zhang S, Datta R . The novel somatostatin receptor 2/dopamine type 2 receptor chimeric compound BIM-23A758 decreases the viability of human GOT1 midgut carcinoid cells. Neuroendocrinology. 2013; 98(2):128-36. DOI: 10.1159/000353784. View

12.

Mole D, Gentilin E, Ibanez-Costa A, Gagliano T, Gahete M, Tagliati F . The expression of the truncated isoform of somatostatin receptor subtype 5 associates with aggressiveness in medullary thyroid carcinoma cells. Endocrine. 2015; 50(2):442-52. DOI: 10.1007/s12020-015-0594-x. View

13.

Sandret L, Maison P, Chanson P . Place of cabergoline in acromegaly: a meta-analysis. J Clin Endocrinol Metab. 2011; 96(5):1327-35. DOI: 10.1210/jc.2010-2443. View

14.

Pivonello C, Rousaki P, Negri M, Sarnataro M, Napolitano M, Marino F . Effects of the single and combined treatment with dopamine agonist, somatostatin analog and mTOR inhibitors in a human lung carcinoid cell line: an in vitro study. Endocrine. 2016; 56(3):603-620. DOI: 10.1007/s12020-016-1079-2. View

15.

Reardon D, Wood S, Brautigan D, Bell G, Dent P, Sturgill T . Activation of a protein tyrosine phosphatase and inactivation of Raf-1 by somatostatin. Biochem J. 1996; 314 ( Pt 2):401-4. PMC: 1217062. DOI: 10.1042/bj3140401. View

16.

Peillon F, Cesselin F, Bression D, Zygelman N, Brandi A, Nousbaum A . In vitro effect of dopamine and L-dopa on prolactin and growth hormone release from human pituitary adenomas. J Clin Endocrinol Metab. 1979; 49(5):737-41. DOI: 10.1210/jcem-49-5-737. View

17.

DeLellis R . The neuroendocrine system and its tumors: an overview. Am J Clin Pathol. 2002; 115 Suppl:S5-16. DOI: 10.1309/7GR5-L7YW-3G78-LDJ6. View

18.

Hofland L . Somatostatin and somatostatin receptors in Cushing's disease. Mol Cell Endocrinol. 2008; 286(1-2):199-205. DOI: 10.1016/j.mce.2007.10.015. View

19.

Mattei A, Ferrari C, Baroldi P, Cavioni V, PARACCHI A, Galparoli C . Prolactin-lowering effect of acute and once weekly repetitive oral administration of cabergoline at two dose levels in hyperprolactinemic patients. J Clin Endocrinol Metab. 1988; 66(1):193-8. DOI: 10.1210/jcem-66-1-193. View

20.

Chowers Y, Cahalon L, Lahav M, Schor H, Tal R, Bar-Meir S . Somatostatin through its specific receptor inhibits spontaneous and TNF-alpha- and bacteria-induced IL-8 and IL-1 beta secretion from intestinal epithelial cells. J Immunol. 2000; 165(6):2955-61. DOI: 10.4049/jimmunol.165.6.2955. View